Man Group’s Citius Pharmaceuticals CTXR Stock Holding History

Man Group’s Portfolio CTXR Stock Details CTXR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-1,848	Closed	-$53.3K	–	1867
2022 Q4	$36.5K	Buy	1,848 +1,348	+270%	+$36.8K	﹤0.01%	1967
2022 Q3	$15K	Buy	+500	New	+$13.7K	﹤0.01%	1948

Other funds holding CTXR

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Man Group's CTXR Position: Q1 2023 in Review

Man Group sold out of Citius Pharmaceuticals (CTXR) in Q1 2023, closing a stake of 1,848 shares — an estimated $53.3K sold.

Man Group first reported a position in CTXR in Q3 2022 and held it in 2 quarters. The position peaked at $36.5K in Q4 2022. 55 funds tracked by Wall St. Rank hold CTXR as of Q1 2023.

Man Group reported no remaining Citius Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
Man Group sold 1,848 Citius Pharmaceuticals shares in Q1 2023, an estimated $53.3K.
Man Group first reported a position in Citius Pharmaceuticals in Q3 2022 and held it in 2 quarters.
Man Group's Citius Pharmaceuticals position peaked at $36.5K in Q4 2022.
55 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q1 2023.

Based on Man Group's 13F filing for Q1 2023, filed 15 May 2023.